To compare the efficacy of a single versus double dose of a proton-pump inhibitor (PPI) in triple therapy for Helicobacter pylori (H. pylori) infection.
Participants included in the review
Studies of participants with H. pylori infection, which had been confirmed using rapid urease test, histology or urea breath test, were eligible for inclusion.
Outcomes assessed in the review
Studies that reported the H. pylori eradication rate, as determined by histology or urea breath test, at least 4 weeks after the end of treatment were eligible for inclusion.
How were decisions on the relevance of primary studies made?
Three reviewers independently assessed the abstracts of the articles identified by the search for inclusion.
Assessment of study quality
The studies were scored for quality using the criteria developed by Chalmers et al., which evaluate the design, implementation and analysis of RCTs. Studies presented as abstracts (n=2) were not scored. The remaining studies were given a quality score that ranged from zero to one, with maximum-quality studies rating one. The authors did not state how the papers were assessed for quality, or how many reviewers performed the quality assessment. 
Data extraction
Three reviewers independently extracted the data and resolved any disagreements by consensus. The eradication rates of H. pylori were calculated by intention-to-treat (ITT) and per protocol analyses.
Methods of synthesis
How were the studies combined?
The studies were combined using Peto's (fixed-effect) method to calculate the pooled Peto odds ratios (ORs) and 95% confidence interval (CIs) for the H. pylori eradication rates.
How were differences between studies investigated?
Heterogeneity was assessed using the Q test, with a cut-off p-value of 0.10.
Data on the eradication rates were analysed separately for the PPIs lansoprazole and pantoprazole, but not for omeprazole and rabeprazole due to insufficient data. A separate subgroup analysis for different combinations of antibiotics (amoxicillin plus clarithromycin, and metronidazole plus clarithromycin at low dose) were also performed. Studies that tested 7-day schedules of triple treatment were also analysed separately.
Results of the review
Eleven studies met the inclusion criteria. Two studies were subdivided into two parts because they analysed four branches of treatment with different durations of eradication therapy. The total number of participants included was 2,391. Seven studies examined lansoprazole (n=1,414), 3 pantoprazole (n=555), 2 omeprazole (n=251) and 1 rabeprazole (n=240).
The quality of the included articles ranged from 0.24 ('acceptable') to 0.74 ('well designed').
The pooled analysis showed that double doses achieved higher H. pylori eradication rates than single doses in both the ITT (83.9% versus 77.7%; OR 1.51, 95% CI: 1.23, 1.85, P<0.01) and per protocol (88.8% versus 80.5%; OR 1.96, 95% CI: 1.51, 2.47, P<0.01) analyses. Heterogeneity was of borderline significance (P<0.10), but diminished with the exclusion of one small study (P=0.23); the main results remained unchanged.
A double dose of PPI was also found to be superior to a single dose in the subgroup analysis of lansoprazole (ITT analysis OR 1.52, 95% CI: 1.16, 2.00, P<0.01); pantoprazole (ITT analysis OR 1.76, 95% CI: 1.19, 2.58, P<0.01); 7-day therapy (ITT analysis OR 1.37, 95% CI: 1.09, 1.72, P not stated); and the combination of clarithromycin (500 mg) and amoxicillin (1 g) antibiotics (5 studies; ITT analysis OR 1.73, 95% CI: 1.38, 2.18, P not stated). There was no significant difference (2 studies) between single and double doses of PPIs for the combination of clarithromycin (250 mg) and metronidazole (500 mg) antibiotics.
